US Corporate Board Director Changes SEC Filings — July 16, 2026

16-07-2026

On July 15, 2026, Snowflake's Compensation Committee granted CEO Sridhar Ramaswamy a performance-based RSU award covering 1,000,000 shares. The award is structured in five tranches with escalating stock price targets (from $324 to $531 per share) over performance periods of 2-7 years, designed to add up to $100 billion in stockholder value. Vesting requires both stock price milestones and continued service through September 2029/2030, with shares subject to a one-year delivery deferral and potential clawback provisions.

• · Stock price targets escalate across five tranches: $324 (2yr), $375 (3yr), $427 (5yr), $479 (7yr), $531 (7yr).
• · Service-based cliff vests on September 15, 2029 for Tranches 1-2 and September 15, 2030 for Tranches 3-5.
• · Delivered shares are subject to a one-year deferral from vesting date.
• · In a Change in Control, performance period ends early; stock price achievement is measured via linear interpolation above $324 per share.
• · Termination by Involuntary Termination, death or disability allows 45-day extension to meet stock price targets.
• · Misconduct or accounting restatement triggers potential full forfeiture/clawback.
• · Award is under Snowflake's 2020 Equity Incentive Plan.

16-07-2026

PJT Partners Inc. announced the appointment of Arun Kalra as Chief Financial Officer, effective October 1, 2026, succeeding Helen Meates, who will step down after more than a decade in the role. Ms. Meates will remain through year-end 2026 to ensure a smooth transition. The filing contains no financial results or period-over-period comparisons, so no quantitative performance data is available.

• · Arun Kalra joined PJT Partners in 2016 as Head of Financial Planning and Analysis and currently serves as Director of Finance.
• · Prior to PJT Partners, Mr. Kalra was a senior member of the compensation team at UBS.
• · Helen Meates has been CFO for more than a decade and will stay on through year-end 2026 to assist with the transition.
• · The effective date of the CFO transition is October 1, 2026.

16-07-2026

Entera Bio Ltd. filed an 8-K on July 16, 2026, to adopt amended Articles of Association, which govern the company's share capital, board powers, and shareholder rights. The filing also covers director/officer changes and other corporate governance matters. No financial results or material transactions were disclosed.

• · The company's authorized share capital is NIS 26,915 divided into 350,000,000 ordinary shares with a nominal value of NIS 0.0000769 each.
• · The Board has broad authority to allot unissued shares, issue options or warrants, and prescribe terms for rights offerings.
• · Share capital may be increased, consolidated, subdivided, or reduced by a shareholder resolution at a General Meeting.
• · Share certificates require signatures of two directors or one director plus the CEO, CFO, or another designee.
• · The Board may make calls on unpaid share amounts with at least 14 Business Days' notice.

16-07-2026

HealthLynked Corp appointed George O'Leary as part-time Interim CFO effective July 13, 2026, replacing Jeremy Daniel who transitioned to a corporate accounting role. The company also eliminated the COO position effective July 24, 2026, with Duncan McGillivray transitioning to a Senior Strategic Advisor role. O'Leary will receive $15,000 per month and 35,000 stock options vesting upon Nasdaq uplisting, which is the company's primary strategic objective.

• · George O'Leary previously served as HealthLynked's CFO from August 6, 2014 until April 4, 2024, and has been a director since August 6, 2014.
• · O'Leary was CEO of Sono Group NV from April 2024 through December 2025, uplisting it from OTCQB to Nasdaq Capital Market in September 2025.
• · O'Leary participated in a SPAC IPO on the NYSE as fractional CFO for New America Acquisition I Corp in December 2025.
• · The COO position elimination is part of ongoing efforts to optimize executive management structure and align with current operational priorities and financial resources.
• · Jeremy Daniel's transition was not due to any disagreement with the company, management, or board.
• · O'Leary's stock options vest only upon successful Nasdaq approval while actively serving as Interim CFO or within the 30-day notice period; otherwise they terminate and are forfeited.
• · O'Leary is engaged as an independent contractor, not an employee, and is not eligible for employee benefits.

16-07-2026

First Interstate BancSystem appointed Matthew Ritter and Kevin Turner as Class II directors on July 13, 2026, filling vacancies created by an increase in board size. Ritter brings finance and real estate experience, while Turner is a former Microsoft COO and Walmart executive. The board now has 13 members, with Ritter serving on the Risk and Technology committees and Turner on the Audit and Technology committees.

• · Ritter has over 25 years of experience in finance, real estate, energy, and private investment.
• · Turner served as COO of Microsoft from 2005 to 2016 and held leadership roles at Walmart from 1985 to 2005, including CEO of Sam's Club.
• · Ritter's investment entity has an existing loan with First Interstate Bank, made in the ordinary course of business on arm's-length terms.
• · Both directors are deemed independent under NASDAQ rules and will receive standard non-employee director compensation.
• · Board composition post-appointment: 4 Class I, 5 Class II, 4 Class III directors.

16-07-2026

ProCap Financial, Inc. elected Benjamin Buchanan as an independent director effective July 15, 2026. Buchanan brings extensive strategic and operational experience, having served as CEO of All Current and in senior roles at LindFast Solutions Group and US Greenfiber. His appointment restores the Audit Committee to three members and brings the Board into compliance with Nasdaq independence requirements, addressing prior governance gaps.

• · Buchanan has served on the board of Argus Monitoring Solutions since February 2022.
• · He earned a degree in Economics from Samford University and an MBA from the University of Kentucky.
• · Buchanan will participate in the Company's standard non-employee director compensation program, prorated from the commencement date.
• · There are no family relationships or reportable transactions between Buchanan and any director or executive officer.

16-07-2026

TD SYNNEX Corporation entered into an updated offer letter with Chief Legal Officer David Vetter on July 10, 2026, formalizing his continued role reporting to the CEO. The new terms include an annual base salary of $670,000, an annual incentive bonus targeted at 100% of base salary, and equity awards valued at approximately $1,500,000. This filing primarily documents an executive compensation arrangement with no financial results or business performance data to assess positive or negative trends.

• · David Vetter reports solely to the CEO.
• · The equity award is split 60% time-based restricted stock and 40% performance-based RSUs.
• · The offer letter includes severance protections for termination without cause or for good reason, including change of control scenarios.
• · The offer letter contains a non-solicitation covenant.
• · The equity grants will be made at the same time as annual grants to all other executive officers.

16-07-2026

John B. Sanfilippo & Son, Inc. announced a leadership transition effective October 1, 2026: CEO Jeffrey T. Sanfilippo will become Executive Chair, COO/President Jasper B. Sanfilippo, Jr. will become CEO, and CFO Frank Pellegrino will add the role of President. The changes are part of a planned succession within the founding family.

• · Jasper B. Sanfilippo, Jr. has been with the company since 1991 and was named COO/President in November 2006.
• · Frank Pellegrino has been with the company since January 2007 and was promoted to CFO in August 2021.
• · The transition is effective October 1, 2026.
• · The filing incorporates by reference related party transaction disclosures from the September 11, 2025 proxy statement.

16-07-2026

SHF Holdings, Inc. appointed Michael Regan as Chief Operating Officer and Secretary on July 15, 2026. Mr. Regan had previously participated in the Company's Series B Convertible Preferred Stock offering on September 30, 2025, which is disclosed as a related party transaction. No other financial metrics or performance data were provided in this filing.

• · Mr. Regan's biographical and compensation information is incorporated by reference from the definitive proxy statement filed on May 8, 2026.
• · The related party transaction (Series B Convertible Preferred Stock offering) is further detailed in the Annual Report on Form 10-K filed on April 15, 2026.
• · No arrangements or understandings exist between Mr. Regan and any other person regarding his appointment.
• · No family relationships exist between Mr. Regan and any director or executive officer.

16-07-2026

Avalanche Treasury Corporation filed an 8-K on July 16, 2026, regarding a director/officer departure or election (Item 5.02). The filing was signed by CEO Gerald Bartholomew Smith, but the specific details of the officer change were not disclosed in the provided text.

• · The filing references Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers).
• · The filing period ends September 30, 2026.
• · No specific details about the officer change (name, role, reason) were included in the provided content.

16-07-2026

AiRWA Inc. announced the resignation of director Chenlong Liu effective July 10, 2026, with no disagreement cited. On July 15, 2026, the board appointed CFO Guibao Ji and independent director Alejandro Quiles to fill the vacancy, with Quiles to chair the Compensation Committee and receive $15,000 per quarter in cash compensation. The appointments are routine governance changes with no related-party transactions.

• · Chenlong Liu's resignation was not due to any disagreement with the company.
• · Guibao Ji will not receive additional compensation for board service beyond his CFO compensation.
• · Alejandro Quiles was determined to be an independent director under Nasdaq Rule 5605(a)(2) and SEC Rule 10A-3.
• · Quiles will also serve on the Nominating and Corporate Governance Committee and the Audit Committee.
• · No family relationships exist between the new directors and any current officers/directors.
• · No related-party transactions reportable under Item 404(a) of Regulation S-K.

16-07-2026

Arhaus, Inc. announced the departure of Jen Porter, Chief Marketing and eCommerce Officer, effective July 15, 2026, as part of a reorganization to separate its Marketing and eCommerce functions under distinct leadership. The company will provide severance benefits to Ms. Porter subject to a customary release of claims. This change reflects a strategic shift to enhance the eCommerce platform, but no financial impact or successor appointment has been disclosed.

• · The separation of Marketing and eCommerce functions is intended to better align organizational structure with strategic objective of enhancing the eCommerce platform.
• · No successor or interim appointment for the Chief Marketing and eCommerce Officer role has been announced.

16-07-2026

Arcutis Biotherapeutics announced the appointment of Christopher 'Chris' Peetz to its Board of Directors, effective July 15, 2026. Peetz is a co-founder and CEO of Mirum Pharmaceuticals with extensive biopharmaceutical leadership experience. This appointment comes as Arcutis focuses on expanding its ZORYVE franchise and pipeline.

• · Chris Peetz has been a co-founder and CEO of Mirum Pharmaceuticals since 2018, leading its global growth.
• · Prior to Mirum, Peetz served as CEO of Flashlight Therapeutics, CFO at Tobira (acquired by Allergan), and held roles at Onyx/Amgen.
• · ZORYVE is described as the number one prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis.
• · ZORYVE has received multiple awards including Allure's 2025 Best of Beauty Breakthrough Award and the National Psoriasis Foundation Seal of Recognition.

16-07-2026

Upwork Inc. disclosed that CFO Erica Gessert will take a temporary medical leave effective July 14, 2026, with an expected return during Q4 2026. During her absence, CEO Hayden Brown will serve as interim principal financial officer without additional compensation. The filing contains no financial results or period-over-period comparisons.

• · CFO Erica Gessert's medical leave begins July 14, 2026, with expected return in Q4 2026.
• · CEO Hayden Brown assumes interim principal financial officer role with no additional compensation.
• · No changes to any plans or arrangements in which Ms. Brown participates as a result of this appointment.
• · No family relationships exist between Ms. Brown and any directors or executive officers.

16-07-2026

Rent the Runway, Inc. filed an 8-K announcing the adoption of its Thirteenth Amended and Restated Certificate of Incorporation, which restates and amends the prior charter. Key changes include authorization of 300 million shares of Class A common stock at $0.001 par value, a classified board with three classes and three-year terms, special meeting rights for 40% voting power holders, and continued indemnification provisions. The filing reflects routine governance updates with no financial or operational impact disclosed.

• · The classified board structure divides directors into three classes with staggered three-year terms.
• · Stockholders holding at least 40% of voting power can call special meetings.
• · Director removal requires cause and a majority vote of shareholders.
• · Newly created directorships and vacancies are filled by the Board (except for designated directors under the Investor Rights Agreement).

16-07-2026

Gyre Therapeutics appointed three new board members effective August 1, 2026: Yue Xiong (CSO), Maxwell Kirkby, and Claire Weston. The appointments expand the board's expertise in scientific, clinical development, and cross-border biopharmaceutical operations. The company also highlighted its pipeline progress, including the NDA acceptance for F351 in CHB-induced liver fibrosis, but noted it owns only a 69.7% equity interest in its commercial-stage subsidiary Gyre Pharmaceuticals.

• · Dr. Xiong has served as CSO since May 2026 and previously served on Cullgen's board and as CSO of Cullgen until its merger with Gyre.
• · Mr. Kirkby co-owns Huang and Kirkby Pharma Consulting (founded May 2024) and previously held leadership roles at BMS, Amgen, and AstraZeneca.
• · Dr. Weston founded Reveal Biosciences (acquired by CellCarta in May 2021) and is now CEO of Tactus AI LLC (since Jan 2025).
• · Gyre's subsidiary Gyre Pharmaceuticals received NMPA acceptance of its NDA for F351 in May 2026; F351 had Breakthrough Therapy designation since March 2021.
• · Gyre owns 69.7% of Gyre Pharmaceuticals as of March 31, 2026.
• · Dr. Xiong was elected as a fellow of AAAS in 2012.

16-07-2026

Primo Brands Corporation announced the resignation of board member Minsok Pak, effective July 14, 2026, due to his acceptance of an executive role with an industry participant, and the appointment of Sudhanshu Priyadarshi to fill the vacancy. Priyadarshi, CFO and President, International of Planet Fitness, brings extensive finance, logistics, and packaged goods experience and will serve on the Audit and Sustainability Committees. The changes are routine board transitions with no disclosed disagreements or material related-party transactions.

• · Mr. Priyadarshi will serve as a director until the 2027 Annual Meeting of Stockholders or until his successor is elected.
• · He will serve on the Board's Audit Committee and Sustainability Committee.
• · Mr. Priyadarshi is a Sponsor Nominee under the Stockholders Agreement dated November 7, 2024.
• · No transactions requiring Item 404(a) disclosure have occurred or are proposed involving Mr. Priyadarshi.
• · Mr. Priyadarshi will receive compensation under the Non-Employee Director Compensation Program and will enter into a standard indemnification agreement.

16-07-2026

Flash Sports & Media Holdings, Inc. (NASDAQ: FLZH) announced the launch of its direct-to-consumer mobile application, FLASHSM, for live and on-demand cricket content and fan engagement, initially available in North America. The app leverages the company's existing production capabilities and its relationship with the Lanka Premier League through subsidiary IPG. While the launch represents a strategic step toward building a cricket-focused platform, the company's business plans remain subject to execution risks, market conditions, and its ability to finance and commercialize its initiatives.

• · The app is currently available in North America on Google Play and Android TV, with streaming also available on the company's website.
• · The app includes features such as live match streaming, highlights, scores, predictions, polling, and fan rewards.
• · The company expects to announce additional features, content, and market availability over the coming months.
• · The filing is an 8-K under Items 5.02, 7.01, and 9.01, but the press release content does not mention any director/officer changes.

16-07-2026

On July 13, 2026, director Shlomo Dovrat informed Unity Software Inc.'s Board of his resignation, effective July 24, 2026. No reason for the departure was disclosed, and no successor or interim arrangement has been announced. The filing does not mention any financial impact or related compensatory changes.

• · Resignation effective July 24, 2026 – an 11-day notice period.
• · No reason for departure or any disagreement with the company was cited.

16-07-2026

Cannae Holdings, Inc. closed the sale of its interest in Brasada Ranch to a company owned by William P. Foley, II on July 15, 2026. In connection with the sale, the Company entered into a letter agreement with Mr. Foley that amends his Director Services Agreement to remove his right to sell 50% of his common stock back to Cannae at defined prices. No financial terms of the sale or any other compensatory changes were disclosed.

• · The letter agreement deletes Section 11(a) of the Director Services Agreement dated May 12, 2025.
• · The amendment removes Mr. Foley's ability to sell 50% of his common stock back to Cannae at defined prices.
• · The sale of Brasada Ranch closed on July 15, 2026.

16-07-2026

Douglas Elliman Inc. appointed Justyn Feldman and Sanghyun Lee as Class III directors to its Board, effective July 10, 2026. Mr. Feldman is a Senior Vice President at The GMS Group, LLC, and Mr. Lee is Head of Asia Pacific, Global Affairs at OpenAI, bringing financial and technology/public policy expertise, respectively. Both directors were determined to be independent under NYSE and SEC rules and will serve until the 2027 annual meeting.

• · Mr. Feldman holds Series 7, 9, 10, 24, 55, 63, and 65 professional licenses and earned a B.S. from the University of Arizona.
• · Mr. Lee holds a B.A. in Economics from Emory University, an MPA from Harvard Kennedy School, an MBA from MIT Sloan, and a Ph.D. from Yonsei University.
• · Both directors will participate in the company's standard non-employee director compensation arrangements as described in the 2026 Proxy Statement.

16-07-2026

Union Bankshares Inc. announced key leadership transitions, including the promotion of Mitchell Kent to Senior Risk Officer following Patricia Hogan's retirement, and the promotion of Carrie Locklin to CFO. Karyn Hale will expand her role as COO. These changes reflect planned succession and are intended to support continued growth, but no financial metrics or performance data were disclosed in the filing.

• · Mitchell Kent joined Union Bank in September 2025 and previously served as a Regional Director with the Consumer Financial Protection Bureau.
• · Carrie Locklin has been with Union Bank since 2006, nearly 20 years.
• · Karyn Hale has been with Union Bank since 2005 and will remain a Vice President of Union Bankshares Inc.
• · Union Bank has received an 'Outstanding' rating for Community Reinvestment Act compliance.
• · Union Bank has been operating since 1891 (135+ years).

16-07-2026

Destiny Media Technologies Inc. appointed Sharath Cherian as CEO effective July 15, 2026, succeeding interim CEO Hyonmyong Cho, who remains Chairman. Cherian, founder of HipHopDX (sold to Warner Music Group), had been serving as a strategic consultant to the company. The filing contains no financial results or period-over-period comparisons.

• · Cherian founded HipHopDX, a music industry media outlet, and sold it to Warner Music Group.
• · Cherian had been serving as a strategic consultant to Destiny for the past year prior to his appointment.
• · Hyonmyong Cho will remain Chairman of the Board after stepping down as Interim CEO.

16-07-2026

BioRestorative Therapies (BRTX) disclosed a major leadership upheaval: CEO/Chairman Lance Alstodt and CFO Robert Kristal resigned for 'Good Reason' on July 13, 2026, claiming a Change in Control occurred, which could trigger up to $2.85M in aggregate severance plus equity acceleration. The Board has not conceded the validity of the claims and has authorized an investigation. Director David Rosa also resigned on July 11. The Board appointed director Katharyn Field as CEO, President, and interim CFO, and elected Esha Randhawa and Steven Brown as new directors, reconstituting all committees. The company faces uncertainty over executive departures and potential severance liabilities.

• · Employment agreements for Alstodt, Kristal, and Silva were amended on July 8, 2026 to restrict Change-in-Control severance triggers to only clause (iii) events (reorganization/merger/asset sale), not clause (i) (50% voting power) or clause (ii) (board change).
• · The resignations of Alstodt and Kristal assert a Change in Control under clause (ii) based on board changes in June 2026 related to a Loan Agreement.
• · The Board has not accepted the validity of the Employment Agreements or the 'Good Reason' claims and has reserved all rights.
• · Pending investigation, no severance payments or benefits will be made except accrued base salary.
• · Katharyn Field was designated as a director by the Lender under the Loan Agreement (disclosed June 12, 2026 8-K).
• · Compensation for Field as executive officer has not yet been determined.
• · New directors Randhawa and Brown are both deemed independent under Nasdaq rules.
• · Board committees were fully reconstituted: Audit (Grasso, Dhaliwal, Randhawa); Compensation (Dhaliwal, Grasso, Brown); Nominating & Governance (Randhawa, Grasso, Dhaliwal, Brown).

16-07-2026

Spruce Power Holding Corporation appointed Bobby L. Owens as General Counsel effective July 13, 2026, with a compensation package including $325,000 base salary, a 60% target bonus, and equity awards. Concurrently, the Board approved the termination of Chief Legal Officer Jonathan Norling, effective date to be determined, with a separation agreement to be disclosed. The changes represent a routine leadership transition without any reported disagreements or related-party transactions.

• · Bobby L. Owens's compensation includes a sign-on restricted stock unit award of $100,000 and annual equity awards valued at 75% of base salary, both vesting in four equal annual installments.
• · The 2026 Annual Award will be prorated based on Mr. Owens's start date.
• · Mr. Owens will participate in the Executive Severance Plan with a multiplier of 1.5x base salary plus full target bonus; from start date through Dec 31, 2026, he receives only 50% of severance benefits, increasing to 100% after Jan 1, 2027.
• · Jonathan Norling's termination date is to be determined by the CEO; the terms of a separation agreement will be disclosed later.

16-07-2026

enGene Holdings Inc. announced board changes, with Michael Heffernan assuming the role of Chairman and Dr. Richard Glickman stepping down after 14 years. The company is preparing for key regulatory milestones, including a pre-BLA meeting with the FDA in 2H 2026, initiation of BLA submission for detalimogene in 2H 2026, and potential FDA approval in 2027. The company is in a strong capital position and focused on commercial readiness for detalimogene in high-risk NMIBC.

• · Michael Heffernan has over 30 years of biopharmaceutical experience and founded Collegium Pharmaceutical.
• · Dr. Richard Glickman served as Chairman for over 14 years and was instrumental in guiding enGene from seed-stage to a publicly listed company.
• · Detalimogene has received RMAT and Fast Track designations from the FDA.
• · The LEGEND trial includes four additional cohorts beyond the pivotal cohort, covering BCG-naïve, BCG-exposed, papillary-only, and polidocanol combination patients.
• · The company is in a strong capital position.

16-07-2026

Gevo announced the appointment of Dr. Todd Werpy to its Board of Directors, effective August 20, 2026. Werpy brings over 30 years of experience in sustainable technologies, R&D, and manufacturing, most recently as Chief Science Officer at ADM. The appointment is expected to strengthen Gevo's board as it pursues growth in low-carbon fuels, renewable chemicals, and carbon management.

• · Werpy holds 36 U.S. patents and over 100 patents globally.
• · He is a recipient of the American Chemical Society's Green Chemistry Award.
• · He co-authored the U.S. Department of Energy report 'Top 12 Value-Added Chemicals from Biomass'.
• · Werpy is a graduate of the Harvard Business School Executive Leadership Program.

16-07-2026

Harmony Biosciences preannounced record Q2 2026 WAKIX net revenue of approximately $261M, up 30% YoY and 21% QoQ, and reaffirmed full-year 2026 revenue guidance of $1.0B-$1.04B. However, CFO Glenn Reicin stepped down effective July 16, 2026, with Stephen Mollichella appointed as Interim Principal Financial Officer; the company does not expect the transition to affect performance.

• · Full Q2 2026 financial results and business updates to be reported on August 4, 2026.
• · Glenn Reicin's departure is not due to any disagreement with the company on operations, policies, or practices.
• · Stephen Mollichella joined Harmony in 2021 and has led financial accounting, reporting, systems, controls, and supported business development.
• · The company is conducting a search for a permanent CFO.